Denali Therapeutics Inc. $DNLI Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 3.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,591,585 shares of the company’s stock after selling 363,738 shares during the quarter. Baillie Gifford & Co. owned about 7.93% of Denali Therapeutics worth $168,310,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Denali Therapeutics by 22.1% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 26,223 shares of the company’s stock worth $381,000 after purchasing an additional 4,739 shares during the period. Campbell & CO Investment Adviser LLC boosted its holdings in Denali Therapeutics by 51.9% during the third quarter. Campbell & CO Investment Adviser LLC now owns 216,774 shares of the company’s stock worth $3,148,000 after buying an additional 74,066 shares in the last quarter. SG Americas Securities LLC acquired a new position in Denali Therapeutics during the third quarter worth about $555,000. KLP Kapitalforvaltning AS grew its position in Denali Therapeutics by 14.6% during the third quarter. KLP Kapitalforvaltning AS now owns 29,900 shares of the company’s stock worth $434,000 after buying an additional 3,800 shares during the period. Finally, Marex Group plc purchased a new position in Denali Therapeutics in the second quarter valued at about $3,665,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on DNLI shares. JPMorgan Chase & Co. boosted their price target on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Morgan Stanley reiterated an “overweight” rating and set a $40.00 target price on shares of Denali Therapeutics in a research report on Thursday, January 8th. UBS Group assumed coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday. Finally, Stifel Nicolaus set a $37.00 price target on shares of Denali Therapeutics in a report on Monday, November 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Buy” and a consensus target price of $32.77.

Denali Therapeutics Stock Down 3.2%

Shares of NASDAQ DNLI opened at $20.25 on Friday. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of -6.96 and a beta of 1.05. The stock’s 50-day simple moving average is $17.88 and its 200-day simple moving average is $15.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.02. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.63) EPS. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 12.50% of the company’s stock.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.